1287766-55-5

Tigulixostat (LC350189) is an orally active, non-purine selective xanthine oxidase inhibitor. Tigulixostat lowers the production of uric acid. Tigulixostat can be used for gout and hyperuricemia study[1][2][3].

[1] Seonghae Yoon, et al. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. DOI:10.2147/DDDT.S86884
[2] Li X, et al. Pharmacological urate-lowering approaches in chronic kidney disease. Eur J Med Chem. 2019 Mar 15;166:186-196. DOI:10.1016/j.ejmech.2019.01.043
[3] Terkeltaub R, et al. Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Arthritis Rheumatol. 2023 Jul;75(7):1275-1284. DOI:10.1002/art.42447